Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants, 50 years of age or older at the time of informed consent
Best Corrected Visual Acuity (BCVA) ≤ 78 and ≥ 24 letters (20/32 to 20/320 Snellen equivalents, respectively) at Screening and at Baseline (Day 1, prior to treatment) visits in the study eye
BCVA of 34 letters (Snellen equivalent 20/200) or better at Baseline (Day 1, prior to treatment) in the non-study eye
You may not be if
Active periocular, ocular, or intraocular infection at baseline (Day 1) (either eye)
Previous or concurrent macular laser treatment (study eye)
Cataract or refractive surgery within 3 months prior to baseline (study eye)
Clareo Health | A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
